» Articles » PMID: 17825343

Modeling How Many Envelope Glycoprotein Trimers Per Virion Participate in Human Immunodeficiency Virus Infectivity and Its Neutralization by Antibody

Overview
Journal Virology
Specialty Microbiology
Date 2007 Sep 11
PMID 17825343
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Trimers of the HIV-1 envelope glycoprotein (Env) effectuate viral entry into susceptible cells. Therefore Env trimers are the targets for neutralizing antibodies. This study models the number of trimers required for virion infectivity. It also delineates the minimum number of antibody molecules that would neutralize a virion. First, Env function was assumed to be incremental (all envelope glycoprotein units contribute equally) or liminal (characterized by thresholds). Then, such models were combined and shown to fit published data on phenotypically mixed pseudotype viruses. Virions with 9 trimers would require around a median of 5 of them for strong infectivity; the proportion varies among strains and mutants. In addition, the models account for both liminal and incremental protomeric effects at the trimer level: different inert Env mutants may affect trimer function in different degrees. Because of compensatory effects at the virion and trimer levels, however, current data cannot differentiate between all plausible models. But the biophysically and mathematically rationalized blurring of thresholds yields candidate models that fit different data excellently.

Citing Articles

Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.

Mahomed S Clin Microbiol Rev. 2024; 37(2):e0015222.

PMID: 38687039 PMC: 11324036. DOI: 10.1128/cmr.00152-22.


Stoichiometry for entry and binding properties of the Env protein of R5 T cell-tropic HIV-1 and its evolutionary variant of macrophage-tropic HIV-1.

Bonner X, Sondgeroth A, McCue A, Nicely N, Tripathy A, Spielvogel E mBio. 2024; 15(4):e0032124.

PMID: 38426750 PMC: 11210212. DOI: 10.1128/mbio.00321-24.


Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.

Ringe R, Colin P, Ozorowski G, Allen J, Yasmeen A, Seabright G PLoS Pathog. 2023; 19(10):e1011601.

PMID: 37903160 PMC: 10635575. DOI: 10.1371/journal.ppat.1011601.


Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.

Colin P, Ringe R, Yasmeen A, Ozorowski G, Ketas T, Lee W Retrovirology. 2023; 20(1):9.

PMID: 37244989 PMC: 10221750. DOI: 10.1186/s12977-023-00624-9.


Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.

Colin P, Ringe R, Yasmeen A, Ozorowski G, Ketas T, Lee W Res Sq. 2023; .

PMID: 36865101 PMC: 9980222. DOI: 10.21203/rs.3.rs-2613503/v1.


References
1.
Chertova E, Bess Jr J, Crise B, Sowder II R, Schaden T, Hilburn J . Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol. 2002; 76(11):5315-25. PMC: 137021. DOI: 10.1128/jvi.76.11.5315-5325.2002. View

2.
Thomas J, Ott D, Gorelick R . Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions. J Virol. 2007; 81(8):4367-70. PMC: 1866140. DOI: 10.1128/JVI.02357-06. View

3.
Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S . Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol. 2002; 77(1):353-65. PMC: 140593. DOI: 10.1128/jvi.77.1.353-365.2003. View

4.
Gallo S, Finnegan C, Viard M, Raviv Y, Dimitrov A, Rawat S . The HIV Env-mediated fusion reaction. Biochim Biophys Acta. 2003; 1614(1):36-50. DOI: 10.1016/s0005-2736(03)00161-5. View

5.
Moore J, Doms R . The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A. 2003; 100(19):10598-602. PMC: 196849. DOI: 10.1073/pnas.1932511100. View